In June 2026, China's National Medical Products Administration approved the world's first solid-tumor CAR-T cell therapy — Shuriciolen-C injection. This is a historic breakthrough: previously CAR-T was mainly used for blood cancers such as leukemia and lymphoma, while solid tumors remained difficult to treat due to complex tumor microenvironments and heterogeneous targets.
With its cell therapy credentials and international service system, Jiahui International Hospital became one of the first institutions to offer solid-tumor CAR-T clinically, completing standardized treatment for the world's first international solid-tumor CAR-T patient — covering indication assessment, leukapheresis, cell manufacturing cycle coordination, and post-infusion follow-up.
For international patients, this is a major step forward: Shanghai now has a complete loop of 'drug approval + clinical application + international service'. Jiahui's collaboration with cross-border platforms such as MedBridge provides pre-screening of medical records, twelve-language communication, and visa and itinerary coordination, ensuring every step from consultation to infusion is standardized and transparent.
How MedBridge Shanghai Helps
As a leading cross-border medical platform in Shanghai, MedBridge Shanghai provides end-to-end support: free medical record review and specialist appointments, pre-travel coordination and visa support, airport pickup and accommodation, full medical interpretation and coordination, and post-treatment follow-up with remote consultations.
For more information on CAR-T treatment options and costs, contact our medical advisors, or explore our medical services and partner hospitals.
[Disclaimer] This article is not medical advice. Indications, costs and availability of cell therapy must be confirmed by in-person physician evaluation and the hospital's official plan.